Versor Investments LP Invests $499,000 in Orthofix Medical Inc. (NASDAQ:OFIX)

Versor Investments LP purchased a new position in Orthofix Medical Inc. (NASDAQ:OFIX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 28,600 shares of the medical device company’s stock, valued at approximately $499,000. Versor Investments LP owned 0.07% of Orthofix Medical at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of OFIX. Assenagon Asset Management S.A. acquired a new stake in Orthofix Medical in the third quarter valued at $216,000. GSA Capital Partners LLP acquired a new stake in Orthofix Medical in the 3rd quarter valued at about $312,000. Victory Capital Management Inc. increased its holdings in Orthofix Medical by 3.3% during the 3rd quarter. Victory Capital Management Inc. now owns 64,807 shares of the medical device company’s stock valued at $1,012,000 after acquiring an additional 2,074 shares in the last quarter. Quest Partners LLC raised its position in Orthofix Medical by 187.1% during the third quarter. Quest Partners LLC now owns 13,908 shares of the medical device company’s stock worth $217,000 after acquiring an additional 9,063 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Orthofix Medical by 17.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 34,632 shares of the medical device company’s stock worth $541,000 after acquiring an additional 5,039 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Massimo Calafiore sold 9,203 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $17.14, for a total value of $157,739.42. Following the sale, the chief executive officer now directly owns 124,151 shares of the company’s stock, valued at approximately $2,127,948.14. This trade represents a 6.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Julie Andrews sold 4,655 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the transaction, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at $506,501.68. This trade represents a 14.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,442 shares of company stock valued at $436,883 over the last quarter. Company insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

OFIX has been the topic of several research reports. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, February 25th. Roth Mkm reissued a “buy” rating and set a $22.00 price target on shares of Orthofix Medical in a research report on Wednesday. Stifel Nicolaus upgraded Orthofix Medical from a “hold” rating to a “buy” rating and upped their price objective for the company from $18.00 to $24.00 in a research report on Friday, November 8th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $24.00 price objective on shares of Orthofix Medical in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Orthofix Medical Trading Up 1.0 %

Shares of OFIX opened at $17.38 on Friday. Orthofix Medical Inc. has a fifty-two week low of $12.08 and a fifty-two week high of $20.73. The company has a market capitalization of $664.16 million, a PE ratio of -5.55 and a beta of 1.10. The stock has a fifty day moving average of $17.93 and a two-hundred day moving average of $17.37. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.